Search for drugs:
Typing the drug name to query
ETRAVIRINE
DIR Classification
Classification:Ambiguous
Severity Score:1.0
Description in Drug Labeling: View Full Labeling: SPL in DailyMed | PDF
- CLINICAL PHARMACOLOGY
- Pharmacodynamics
- Cardiac Electrophysiology
- In a thorough QT/QTc study in 41 healthy subjects, INTELENCE 200 mg twice daily or 400 mg once daily did not affect the QT/QTc interval.
Postmarketing Surveillance
Contingency Table:
Current Drug
Other Drugs
QT Prolongation
1
24091
Other ADRs
2240
38379347
Odds Ratio = 0.712
Drug Property Information
ATC Code(s):
- J05AG04 - etravirine
- J05AG - Non-nucleoside reverse transcriptase inhibitors
- J05A - DIRECT ACTING ANTIVIRALS
- J05 - ANTIVIRALS FOR SYSTEMIC USE
- J - ANTIINFECTIVES FOR SYSTEMIC USE
Active Ingredient:etravirine
Active Ingredient UNII:0C50HW4FO1
Drugbank ID:DB06414
PubChem Compound:193962
CTD ID: C451734
PharmGKB:PA166014703
CAS Number:269055-15-4
Dosage Form(s):tablet
Route(s) Of Administrator:oral
Daily Dose:
- 400.0 mg/day J05AG04
Chemical Structure: 
SMILE Code:
CC1=CC(=CC(C)=C1OC1=C(Br)C(N)=NC(NC2=CC=C(C=C2)C#N)=N1)C#N
CC1=CC(=CC(C)=C1OC1=C(Br)C(N)=NC(NC2=CC=C(C=C2)C#N)=N1)C#N
Reference
N/A
Disclaimer:
The content of this database of QT prolongation is intended for educational and scientific research purposes only. It is not intended as a substitute for professional medical advice, diagnosis or treatment.
Any mention of commercial products is for clarification and not intended as endorsement.